Deep brain stimulation
This article was originally published in The Gray Sheet
Executive Summary
Deep brain stimulation is "a treatment option" for patients suffering from Parkinson's disease with motor complications, new guidelines from the American Academy of Neurology suggest. The April 3 release of the guidelines was welcome news to Medtronic, which manufactures Activa, one of the deep brain stimulators on the market used to treat that condition. The firm is seeking to broaden the use of Activa to treat obsessive-compulsive disorder and depression (1"The Gray Sheet" April 4, 2005, p. 16)...
You may also be interested in...
Medtronic To Seek HDE For Activa To Treat Obsessive-Compulsive Disorder
Medtronic's pursuit of Activa deep-brain stimulation to treat chronic obsessive-compulsive disorder will serve as a springboard to the lucrative depression market, the company predicts
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.